Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000623280 | SCV000741470 | likely pathogenic | Inborn genetic diseases | 2020-11-16 | criteria provided, single submitter | clinical testing | The c.494T>C (p.L165P) alteration is located in exon 2 (coding exon 1) of the ECEL1 gene. This alteration results from a T to C substitution at nucleotide position 494, causing the leucine (L) at amino acid position 165 to be replaced by a proline (P). Based on data from the Genome Aggregation Database (gnomAD) database, the ECEL1 c.494T>C alteration was observed in 0.004% (7/183120) of total alleles studied, with a frequency of 0.03% (7/25980) in the South Asian subpopulation. This alteration has been detected in the homozygous state multiple patients with a clinical phenotype consistent with ECEL1-related multiple congenital contractures (Ambry internal data; North Thames Genomic Laboratory Hub personal communication). In addition, this alteration was reported in trans with a second missense variant in a patient with distal arthrogryposis (Lindstrand, 2019). This amino acid position is conserved in available mammalian species. The p.L165P alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. |
Rare Disease Group, |
RCV000787365 | SCV000926327 | uncertain significance | Arthrogryposis multiplex congenita | 2019-04-09 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001756022 | SCV001987840 | pathogenic | not provided | 2025-01-10 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25099528, 37273706, 25708584, 24782201, 23261301, 23236030, 34940998, 30919572, 33726816, 36002593, 31694722) |
Centogene AG - |
RCV001809702 | SCV002059566 | uncertain significance | Distal arthrogryposis type 5D | 2020-02-27 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001809702 | SCV003831371 | uncertain significance | Distal arthrogryposis type 5D | 2020-08-06 | criteria provided, single submitter | clinical testing |